Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Further Strengthens CRISPR\/Cas IP Portfolio With Patent Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbial Gene Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"SNIPR Biome Receives Funding from CARB-X to Support Advancement of CRISPR-medicine SNIPR001 into Clinical Trials in Haematological Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SNIPR Biome Receives Funding for CRISPR-Medicines to Improve EED in Pregnant Women","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by SNIPR Biome

    Menu

    SNIPR Biome

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              SNIPR Biome

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR Biome Receives Funding for CRISPR-Medicines to Improve EED in Pregnant Women

              Details:

              The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.

              Lead Product(s): Undisclosed

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding June 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SNIPR Biome

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR Biome Receives Funding from CARB-X to Support Advancement of CRISPR-medicine SNIPR001 into Clinical Trials in Haematological Cancer Patients

              Details:

              The funding is intended to aid SNIPR Biome in advancing CRISPR-medicine SNIPR001, which is currently undergoing early-stage clinical trials for treating E. coli bloodstream infections in patients with hematological cancer.

              Lead Product(s): SNIPR001

              Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: CARB-X

              Deal Size: $5.4 million Upfront Cash: Undisclosed

              Deal Type: Funding April 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SNIPR Biome

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbial Gene Therapy

              Details:

              SNIPR001 is a novel, first-in-human, CRISPR-based microbial gene therapy, developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.

              Lead Product(s): SNIPR001

              Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SNIPR Biome

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR Biome Further Strengthens CRISPR/Cas IP Portfolio With Patent Grant

              Details:

              SNIPR’s CRISPR technology provides a highly selective way to target individual bacterial strains for killing which can be useful for the prevention and treatment of any indication where a specific bacterial strain is the underlying cause of a disease.

              Lead Product(s): SNIPR001

              Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SNIPR Biome

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes

              Details:

              SNIPR001, is the first orally dosed CRISPR-based therapeutic candidate and CRISPR-armed bacteriophage cocktail that targets antibiotic-resistant E. coli infections in hematological cancer patients.

              Lead Product(s): SNIPR001

              Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SNIPR Biome

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage

              Details:

              SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients.

              Lead Product(s): SNIPR001

              Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SNIPR Biome

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

              Details:

              The experimental CRISPR therapeutic, SNIPR001, is designed to selectively target and eradicate E. coli in the gut, thus preventing translocation of these bacteria to the bloodstream, in a high-risk population of hematological cancer patients at risk for neutropenia.

              Lead Product(s): SNIPR001

              Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SNIPR Biome

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections

              Details:

              INDA approval is based on the positive pre-clinical data for SNIPR001 which showed that it holds a huge potential against life-threatening infections and also in modulating microbiome-associated diseases.

              Lead Product(s): SNIPR001

              Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY